Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Chinese Academy of Medical Sciences & Peking Union Medical College · Shanghai Pulmonary Hospital · +30 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
383
total citations
- FWCI
- 36.31
- Percentile
- 100%
- References
- 19
Citations per year
Authors
81Topics & keywords
Topics
Keywords
- Medicine
- Carboplatin
- Internal medicine
- Placebo
- Population
- Lung cancer
- Clinical endpoint
- Response Evaluation Criteria in Solid Tumors
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.